Abstract
Background How the prevalence of atrial fibrillation (AF) differs between various demographic subgroups of acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT) in the United States (US) is unknown. Data on whether AF prevalence in MT admissions changed over the last decade are sparse.
Methods We conducted a serial cross-sectional study using all primary AIS discharges in the 2010-2020 National Inpatient Sample. Discharges with MT codes were identified (n=155,277) and the proportion with AF in various age, sex and racial subgroups were computed. We used multivariable-adjusted negative binomial regression to compare AF prevalence between demographic subgroups and Joinpoint regression to evaluate trends over time. Multivariable-adjusted generalized linear models were used to evaluate the association of AF with in-hospital outcomes.
Results Across the study period, 45.0% of AIS discharges with MT had AF but marked disparity existed by age, sex and race. After multivariable adjustment, AF prevalence was 4% higher in women vs. men (prevalence rate ratio [PRR] 1.04, 95%CI 1.01-1.07), was lower in Black vs White (PRR 0.80, 95%CI 0.77-0.84) but higher in Asian compared to White discharges (PRR 1.11, 95%CI 1.05-1.18). Prevalence increased with age (PRR for ≥80 years vs 18-39 years: 5.23, 95%CI 4.28-6.39). Following joinpoint regression, prevalence increased by 3.2% (95%CI 1.3 to 5.2%) annually across the period 2010-2015 but declined by -2.2% (95%CI -2.9% to -1.4%) from 2015-2020. AF was associated with 27% lower odds of in-hospital mortality (Odds ratio 0.72, 95%CI 0.62-0.84) and 31% greater odds of routine home discharge (Odds ratio, 95%CI 1.17 to 1.47) compared to no AF.
Conclusion AF prevalence in MT patients in the US is approximately twice that of the general AIS population but marked disparity exists by age, sex and race. AF Prevalence in MT increased from 2010-2015 but declined in the period 2015-2020.
What is new?
Approximately 45% of mechanical thrombectomy acute ischemic stroke hospitalizations have comorbid atrial fibrillation (AF) and this proportion increases with age with 70% of patients >=80 years having AF.
In contrast to all AIS patients, in the subset of AF patients undergoing MT, AF is associated with reduced in-hospital mortality and better odds of routine home discharge.
What are the clinical implications?
Given the post-stroke CHA2DS2-VASc score of at least 2, almost half of all MT patients in the US may be potential candidates for therapeutic anticoagulation.
Competing Interest Statement
Dr Chaturvedi is an associate editor for the Stroke journal and Dr Otite is on the Stroke journal editorial board. The other authors have no relevant disclosures
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval not needed according to the Healthcare Cost and Utilizations Project
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Twitter handles: @oliverotite @chaturvedineuro @dockhandelwal @upstateneuro @perfuseincuse @DevinJBurkeMD @namorrismd @smitdpat @anikpezie
Data Availability
All data used in this study can be purchased directly from the Healthcare Cost and Utilization Project. The authors are bound by data use agreeement not to share HCUP data
